Andrew Sandham
Chairman
Has 30 years of experience in the healthcare industry. He was CEO and Co-Founder of Ionix Pharmaceuticals and has served as Chief Operating Officer of Signature BioScience, Hexagen and Cantab Pharmaceuticals, having worked in business development and marketing positions at Roche, Celltech and Amersham. Andy is also a Venture Partner at Abingworth LLP.
Dr Melanie Lee
Chief Executive Officer
Dr Lee was formerly President of New Medicines and Executive Vice President R&D with UCB, having served as R&D Director at Celltech before its merger with UCB. Dr Lee brings a wealth of drug research and development experience to Syntaxin, through her early academic career at Cancer Research UK (as ICRF), a decade in research with GlaxoSmithKline and her later leadership of biopharmaceutical R&D at Celltech and UCB. Dr Lee currently Chairs Cancer Research Technology, an early drug R&D and technology licensing company of CRUK.
Dr Nigel Clark
Chief Business Officer
Over 15 years of commercial and managerial experience in the biotech and pharma industry. Dr Clark was formerly Vice-President of business development at Vernalis and a member of the senior executive committee as well as President, Vernalis Canada. Dr Clark has also held leadership roles at Ribotargets and British Biotech and was co-head of the biotech business unit at Datamonitor.
Dr Phil Boyd
Chief Financial Officer
Over 20 years' broad financial and management experience.
Biotechnology exposure as UK Finance Director, Evotec AG and Finance Director at Cambridge Discovery Chemistry
Ltd. Prior experience in management consulting and a scientific background.
Dr Jon Court
Chief Development Officer & Research Director
Over 30 years' of pharmaceutical research and development experience. He has held R&D roles with Wellcome and Roche and was the founder and CEO of Fulcrum Pharma plc, an international contract drug development business engaged in global NCE and NBE development.
Dr Richard Jones
Chief Medical Officer
Richard Jones has 20 years' experience as a Physician executive with broad, international project and senior management experience in the pharmaceutical industry holding senior positions at Aspreva, Syngenta, Johnson and Johnson and Hoffman La Roche. His extensive background in drug development in both small molecules and Biologicals cuts across all therapeutic areas and all stages of the drug development process.
Dr Keith Foster
Founder & Chief Technology Officer
Over 20 years' management experience in pharmaceutical R&D, including positions with SmithKline Beecham and Ipsen. He led the team that developed the proprietary technology that is the basis of Syntaxin, and played a lead role in developing the analgesic application of the technology. He has extensive experience in intellectual property management and development of a patent portfolio.
Dr John Chaddock
Head of Molecular Biology & Research Logistics
Experience at CAMR where he was instrumental in directing the activities of multi-disciplinary teams focussed
toward the development of novel therapeutics based on bacterial proteins. Dr Chaddock has a track record of developing
candidate molecules for the selection of pre-clinical studies and expertise in patent management.